Relmada Therapeutics, Inc.

NasdaqGS:RLMD 주식 보고서

시가총액: US$99.0m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Relmada Therapeutics 관리

관리 기준 확인 2/4

Relmada Therapeutics' CEO는 Sergio Traversa, Apr2012 에 임명되었습니다 의 임기는 12.17 년입니다. 총 연간 보상은 $ 4.78M, 14.7% 로 구성됩니다. 14.7% 급여 및 85.3% 보너스(회사 주식 및 옵션 포함). 는 $ 739.40K 가치에 해당하는 회사 주식의 0.81% 직접 소유합니다. 739.40K. 경영진과 이사회의 평균 재임 기간은 각각 4.4 년과 4.4 년입니다.

주요 정보

Sergio Traversa

최고 경영자

US$4.8m

총 보상

CEO 급여 비율14.7%
CEO 임기12.5yrs
CEO 소유권1.3%
경영진 평균 재임 기간4.8yrs
이사회 평균 재임 기간4.8yrs

최근 관리 업데이트

Recent updates

Relmada Therapeutics: Run Up Into Results May Resume Following This Drop

Mar 21

Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

Mar 13
Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark

Jan 14

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Dec 04
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

Aug 29
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

May 07
We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Dec 15
We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure

Oct 14

Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up

Sep 14

Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression

Aug 09

We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely

Jul 14
We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Feb 26
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

4 Clinical Catalysts On Tap For Relmada In 2022

Jan 28

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

Nov 04
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

Our First Look At Relmada Therapeutics

Jun 28

We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Jun 28
We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

Mar 09
Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?

Jan 15
What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?

Enrollment underway in Relmada Therapeutics' late-stage depression study with REL-1017

Dec 07

Relmada Therapeutics (RLMD) Investor Presentation - Slideshow

Dec 02

Relmada Therapeutics (RLMD) Investor Presentation - Slideshow

Nov 16

CEO 보상 분석

Sergio Traversa 의 보수는 Relmada Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$87m

Mar 31 2024n/an/a

-US$94m

Dec 31 2023US$5mUS$701k

-US$99m

Sep 30 2023n/an/a

-US$112m

Jun 30 2023n/an/a

-US$129m

Mar 31 2023n/an/a

-US$144m

Dec 31 2022US$3mUS$668k

-US$157m

Sep 30 2022n/an/a

-US$153m

Jun 30 2022n/an/a

-US$157m

Mar 31 2022n/an/a

-US$143m

Dec 31 2021US$36mUS$630k

-US$126m

Sep 30 2021n/an/a

-US$112m

Jun 30 2021n/an/a

-US$86m

Mar 31 2021n/an/a

-US$71m

Dec 31 2020US$900kUS$600k

-US$59m

Sep 30 2020n/an/a

-US$43m

Jun 30 2020n/an/a

-US$30m

Mar 31 2020n/an/a

-US$23m

Dec 31 2019US$16mUS$214k

-US$15m

Sep 30 2019n/an/a

-US$18m

Jun 30 2019n/an/a

-US$17m

Mar 31 2019n/an/a

-US$17m

Dec 31 2018n/an/a

-US$17m

Sep 30 2018n/an/a

-US$11m

Jun 30 2018US$975kUS$376k

-US$9m

보상 대 시장: Sergio 의 총 보상 ($USD 4.78M )은 US 시장( $USD 680.04K ).

보상과 수익: 회사가 수익성이 없는 동안 Sergio 의 보상이 증가했습니다.

CEO

Sergio Traversa (64 yo)

12.5yrs

테뉴어

US$4,778,944

보상

Dr. Sergio Traversa, PharmD, MBA has been the Chief Executive Officer and a Director of Relmada Therapeutics, Inc. since April 18, 2012. Dr. Traversa served as Interim Chief Financial Officer at Relmada Th...

리더십 팀

이름위치테뉴어보상소유권
Sergio Traversa
CEO & Director12.5yrsUS$4.78m1.27%
$ 1.3m
Maged Shenouda
Chief Financial Officer4.8yrsUS$2.34m0.29%
$ 289.7k
Charles Ence
Chief Accounting & Compliance Officer4.8yrsUS$2.33m0.13%
$ 127.8k
Paolo Manfredi
Chief Scientific Officer4yrs데이터 없음데이터 없음
Gina DiGuglielmo
VP & Head of Clinical Operations5.5yrs데이터 없음데이터 없음
Marco Pappagallo
Chief Clinical Officer4yrs데이터 없음데이터 없음
John Hixon
Head of Commercial2.3yrs데이터 없음데이터 없음
Andrew Cutler
Senior Clinical Development Advisorno data데이터 없음데이터 없음
Richard Mangano
Consultant7.5yrs데이터 없음데이터 없음

4.8yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 관리: RLMD 의 관리팀은 경험 ( 4.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Sergio Traversa
CEO & Director12.5yrsUS$4.78m1.27%
$ 1.3m
Maged Shenouda
Chief Financial Officer4.8yrsUS$2.34m0.29%
$ 289.7k
Charles Casamento
Independent Chairman of the Board9.3yrsUS$674.90k0.043%
$ 42.6k
Stephen Stahl
Member of Scientific Advisory Board4.8yrs데이터 없음데이터 없음
Maurizio Fava
Member of Scientific Advisory Board7.3yrs데이터 없음데이터 없음
Fabiana Fedeli
Independent Director1.8yrsUS$1.33m0%
$ 0
Paul Kelly
Director8.9yrsUS$1.67m0.70%
$ 696.3k
Charles Inturrisi
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
John Glasspool
Independent Director4.8yrsUS$604.77k데이터 없음
Luca Pani
Member of Scientific Advisory Board4.8yrs데이터 없음데이터 없음
Dan Iosifescu
Member of Scientific Advisory Board4.8yrs데이터 없음데이터 없음
Sanjay Mathew
Member of Scientific Advisory Board4.8yrs데이터 없음데이터 없음

4.8yrs

평균 재임 기간

62.5yo

평균 연령

경험이 풍부한 이사회: RLMD 의 이사회는 경험(평균 재직 기간 4.4 년)으로 간주됩니다.